PRESS RELEASE published on 12/11/2025 at 07:00, 9 months 1 day ago Informations privilégiées / Autres communiqués Innate Pharma publie son calendrier financier pour 2026, incluant la publication des résultats annuels et semestriels, ainsi que des chiffres d'affaires trimestriels Chiffre D'affaires Calendrier Financier Résultats Annuels Innate Pharma Immunothérapies
PRESS RELEASE published on 12/11/2025 at 07:00, 9 months 1 day ago Inside Information / Other news releases Innate Pharma releases its 2026 financial calendar, including key dates for financial statements and shareholder meetings. Find details on the company's website Euronext Financial Calendar Nasdaq Innate Pharma 2026
BRIEF published on 11/28/2025 at 07:05, 9 months 14 days ago Nouveau nombre d'actions et droits de vote d'Innate Pharma Euronext Paris Capital Social Nasdaq Innate Pharma Actions Et Droits
BRIEF published on 11/28/2025 at 07:05, 9 months 14 days ago New number of shares and voting rights of Innate Pharma Euronext Paris Share Capital Nasdaq Innate Pharma Shares And Rights
PRESS RELEASE published on 11/28/2025 at 07:00, 9 months 14 days ago Informations privilégiées / Autres communiqués Innate Pharma communique le nouveau nombre d'actions et de droits de vote au 27 novembre 2025 selon la réglementation en vigueur avec 92 196 523 actions ordinaires et 92 962 943 droits de vote théoriques Droits De Vote Actions AMF Innate Pharma Biotechnologies
BRIEF published on 11/17/2025 at 07:05, 9 months 25 days ago Innate Pharma to Present at Jefferies Global Healthcare Conference Biotechnology Immunotherapy Innate Pharma Jefferies Conference Antibody Therapeutics
BRIEF published on 11/17/2025 at 07:05, 9 months 25 days ago Innate Pharma présentera ses travaux lors de la conférence mondiale sur les soins de santé de Jefferies. Biotechnologie Immunothérapie Innate Pharma Conférence Jefferies Thérapeutiques Par Anticorps
PRESS RELEASE published on 11/17/2025 at 07:00, 9 months 25 days ago Informations privilégiées / Autres communiqués Innate Pharma présentera lors de la Jefferies Global Healthcare Conference à Londres le 17 novembre 2025. La société développe des traitements d'immunothérapies contre le cancer Société Cancer Innate Pharma Jefferies Global Healthcare Conference Immunothérapies
PRESS RELEASE published on 11/17/2025 at 07:00, 9 months 25 days ago Inside Information / Other news releases Innate Pharma to present at Jefferies Global Healthcare Conference on November 17, 2025. A global biotechnology company focusing on cancer immunotherapies Biotechnology Immunotherapy Cancer Innate Pharma Jefferies Global Healthcare Conference
BRIEF published on 10/14/2025 at 07:05, 10 months 29 days ago Innate Pharma Highlights Lacutamab at Analyst and Investor Event Investors Clinical Trial Innate Pharma Lacutamab Sézary Syndrome
Published on 09/12/2026 at 02:35, 11 hours 44 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 19 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 14 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 54 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 19 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 48 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 16 hours 4 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 8 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 34 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 20 hours 3 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
